Tech Company Financing Transactions

Frequency Therapeutics Funding Round

Frequency Therapeutics secured a $62 million Series C funding round on 7/24/2019. Investors included Perceptive Advisors, Axil Capital and Cobro Ventures.

Transaction Overview

Company Name
Frequency Therapeutics
Announced On
7/24/2019
Transaction Type
Venture Equity
Amount
$62,000,000
Round
Series C
Investors

Perceptive Advisors (Lead Investor) (Joseph Edelman)

Axil Capital (Fred Shane)

Cobro Ventures (Marc Cohen)

Deerfield Capital

Mizuho Capital of Japan

Polaris Partners

RTW Investments

Taiwania Capital (Michael Huang)

Proceeds Purpose
Frequency will use the proceeds to support the clinical development of FX-322, a regenerative therapeutic for the treatment of sensorineural hearing loss that is moving into a Phase 2a study, and to advance discovery programs in other therapeutic areas using its proprietary Progenitor Cell Activation (PCA) platform.

Company Information

Company Status
Publicly-held
Industry
Biopharmaceutical
Mailing Address
19 Presidential Way
Woburn, MA 01801
USA
Phone
(781) 235-3060
Website
www.frequencytx.com
Email Address
[email protected]
Overview
Frequency Therapeutics (Nasdaq: FREQ) develops small molecule drugs that activate progenitor cells within the body to restore healthy tissue. Through the transitory activation of these progenitor cells, Frequency enables disease modification without the complexity of genetic engineering.
Profile
Frequency Therapeutics LinkedIn Company Profile
Social Media
Frequency Therapeutics Company Twitter Account
Company News
Frequency Therapeutics News
Facebook
Frequency Therapeutics on Facebook
YouTube
Frequency Therapeutics on YouTube

Management Team

Title
Name
Email & Social
Chief Executive Officer
David Lucchino
  David Lucchino LinkedIn Profile  David Lucchino Twitter Account  David Lucchino News  David Lucchino on Facebook
Chief Medical Officer
William Chin
  William Chin LinkedIn Profile  William Chin Twitter Account  William Chin News  William Chin on Facebook
Chief Scientific Officer
Chris Loose
  Chris Loose LinkedIn Profile  Chris Loose Twitter Account  Chris Loose News  Chris Loose on Facebook
Vice President
William Mclean
  William Mclean LinkedIn Profile  William Mclean Twitter Account  William Mclean News  William Mclean on Facebook
VP - Bus. Development
Carl Lebel
  Carl Lebel LinkedIn Profile  Carl Lebel Twitter Account  Carl Lebel News  Carl Lebel on Facebook
VP - Bus. Development
Ajay Rai
  Ajay Rai LinkedIn Profile  Ajay Rai Twitter Account  Ajay Rai News  Ajay Rai on Facebook
VP - R & D
Scott Eliasof
  Scott Eliasof LinkedIn Profile  Scott Eliasof Twitter Account  Scott Eliasof News  Scott Eliasof on Facebook

 

 

Browse more venture capital transactions:

Prev: 7/24/2019: TurnKey Vacation Rentals venture capital transaction
Next: 7/24/2019: Heap venture capital transaction

 

Share this article

 

About Our Venture Capital Transactions Database

We do our best to report on funding rounds that are announced publicly. VC transactions on this site are derived from publicly available VC deal announcements. The data comes to us via our partnership with VentureDeal.com, an affiliated venture.

 

Additional Resources for Entrepreneurs

Lists of Venture Capital and Private Equity Firms

Franchise Opportunities

Contributors

Business Glossary

 

Copyright © 2001-2024. Gaebler Ventures. All rights reserved.